At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 268 enrolled
Drug / intervention
oral esomeprazole 20 mg twice daily +1 moredrug
Likely dose
oral esomeprazole 20 mg twice dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Secondary Prevention With Long-term Oral Esomeprazole for Peptic Ulcer Recurrence and Rebleeding in High-risk Rockall Scores ≥ 6 Patients
In Brief
A Phase 4 clinical trial evaluating oral esomeprazole 20 mg twice daily and oral esomeprazole 20 mg once daily for Peptic Ulcer Hemorrhage. Completed, enrolled 268 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether a long-term prophylactic use of esomeprazole 20 mg twice daily or once daily has prevention effectiveness in reducing the recurrence of peptic ulcer bleeding after ulcer healed with 16-week oral esomeprazole therapy in high-risk patients whose Rockall score ≥ 6.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeptic Ulcer Hemorrhage
CountriesTaiwan
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedMay 2015
Primary CompletionDec 2020
TodayJul 2026
First PostedMay 28, 2015
Enrollment StartApr 1, 2015
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 11.1 years ago
Interventions
oral esomeprazole 20 mg twice dailydrug
for 36 weeks
oral esomeprazole 20 mg once dailydrug
for 36 weeks